Research programme: anticancer drug conjugates - Elucida Oncology
Latest Information Update: 14 Jan 2021
At a glance
- Originator Elucida Oncology
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins
- Mechanism of Action DNA topoisomerase I inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Brain cancer; Glioma; Ovarian cancer
Most Recent Events
- 12 Jan 2021 Elucida Oncology plans a clinical trial for Cancer in second half of 2021
- 26 Oct 2020 Preclinical trials in Ovarian cancer in USA (Parenteral) before October 2020 (Elucida Oncology pipeline, October 2020)
- 01 Oct 2020 Preclinical trials in Brain cancer in USA before October 2020 (Elucida Oncology pipeline, October 2020)